Irene Kraus Christiansen
Overview
Explore the profile of Irene Kraus Christiansen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pretet J, Arroyo Muhr L, Cuschieri K, Fellner M, Correa R, Picconi M, et al.
J Clin Virol
. 2024 Feb;
171:105657.
PMID: 38401369
Background: Some high-grade cervical lesions and cervical cancers (HSIL+) test negative for human papillomavirus (HPV). The HPV-negative fraction varies between 0.03 % and 15 % between different laboratories. Monitoring and...
2.
Mandishora R, Rounge T, Fitzpatrick M, Christiansen I, Ambur O, Lagstrom S, et al.
PLoS One
. 2023 Jul;
18(7):e0288418.
PMID: 37418482
[This corrects the article DOI: 10.1371/journal.pone.0250426.].
3.
Hesselberg Lovestad A, Stosic M, Costanzi J, Christiansen I, Aamot H, Ambur O, et al.
Virol J
. 2023 Mar;
20(1):44.
PMID: 36890572
Background: Previously developed TaME-seq method for deep sequencing of HPV, allowed simultaneous identification of the human papillomavirus (HPV) DNA consensus sequence, low-frequency variable sites, and chromosomal integration events. The method...
4.
Hesselberg Lovestad A, Repesa A, Costanzi J, Lagstrom S, Christiansen I, Rounge T, et al.
Tumour Virus Res
. 2022 Sep;
14:200247.
PMID: 36100161
Persistent infection with Human Papillomavirus (HPV) is responsible for almost all cases of cervical cancers, and HPV16 and HPV18 associated with the majority of these. These types differ in the...
5.
Aasbo G, Trope A, Nygard M, Christiansen I, Baasland I, Iversen G, et al.
Br J Cancer
. 2022 Aug;
127(10):1816-1826.
PMID: 35995936
Background: Cervical cancer screening participation is suboptimal in most settings. We assessed whether human papillomavirus (HPV) self-sampling may increase screening participation among long-term non-attenders in Norway. Methods: A pragmatic randomised...
6.
Nygard M, Engesaeter B, Castle P, Berland J, Eide M, Iversen O, et al.
Cancer Epidemiol Biomarkers Prev
. 2022 Jul;
31(9):1812-1822.
PMID: 35793700
Background: Cervical cancer screening programs are facing a programmatic shift where screening protocol based on human papillomavirus testing (HPV-Screening protocol) is replacing the liquid-based cytology (LBC-Screening protocol). For safe technology...
7.
Lagstrom S, Hesselberg Lovestad A, Umu S, Ambur O, Nygard M, Rounge T, et al.
Tumour Virus Res
. 2021 Jun;
12:200221.
PMID: 34175494
Human papillomavirus (HPV) 16 and 18 are the most predominant types in cervical cancer. Only a small fraction of HPV infections progress to cancer, indicating that additional factors and genomic...
8.
Mandishora R, Rounge T, Fitzpatrick M, Christiansen I, Ambur O, Lagstrom S, et al.
PLoS One
. 2021 Apr;
16(4):e0250426.
PMID: 33901223
Background & Aim: Women with HIV/HPV coinfection and cervical lesions are at increased risk of developing HPV related anal cancer. Self-collection of anal swabs may facilitate HPV molecular testing in...
9.
Bhatia R, Alcaniz Boada E, Bonde J, Quint W, Christiansen I, Xu L, et al.
J Virol Methods
. 2021 Apr;
294:114161.
PMID: 33895238
Aim: The VALidation of HPV GENotyping Tests (VALGENT) is a framework for comparison and validation of HPV tests with genotyping capabilities. In this study, the clinical performance of a single...
10.
Ejegod D, Hansen M, Christiansen I, Pedersen H, Quint W, Xu L, et al.
J Clin Virol
. 2020 May;
128:104336.
PMID: 32446166
Background: The VALidation of HPV Genotyping Tests (VALGENT) framework is an international cooperation designed for comparison and clinical validation of HPV assays with genotyping capabilities. Objectives: Here we addressed the...